TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00796419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% human albumin
Description: Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hetastarch
Description: Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
Study: NCT00665457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT03290651

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Natural Health Product - RepHresh Pro-B
Description: Participants will take the probiotic or placebo daily for 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take the probiotic or placebo daily for 90 days.
Study: NCT00665457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study: NCT00691275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study: NCT03482596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reducing/breaking prolonged sitting
Description: The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour.
Study: NCT00691275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT02335281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT
Description: Standardized FMT once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 2g Po perday
Study: NCT00283335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemfibrozil
Study: NCT02609490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan tablets
Description: 20mg/tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan placebo tablets
Description: placebo tablet
Study: NCT00283335

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets taken once per day
Study: NCT02609490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil tablets
Description: 20mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil placebo tablets
Description: placebo tablet
Study: NCT02026141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Study: NCT01870596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHK1 Inhibitor SCH 900776
Description: Given IV
Study: NCT02586558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Infant formula
Description: Ready-to-feed infant formula to be fed ad libitum
Study: NCT01870596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02586558

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference group
Description: Ready-to-feed infant formula to be fed ad libitum
Study: NCT00665457

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Study: NCT03160235

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Study: NCT00578734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucinactant
Description: Slow intra-tracheal instillation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Slow intra-tracheal instillation
Study: NCT00665457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging biomarker analysis
Study: NCT02381691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maternal breast milk odor
Study: NCT00665457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study: NCT02381691

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no odor
Study: NCT00665457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Study: NCT01724268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pred + Meth
Description: PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti TNF + Meth
Study: NCT04044508

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketocal 4:1 liquid Nutricia (intervention)
Description: Modified ketogenic diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fortini multifibre Nutrica (placebo)
Description: Placebo diet
Study: NCT03911388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G207
Description: Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.
Study: NCT00666770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime
Study: NCT00900562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalypsis ( PM00104)
Description: Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
Study: NCT01368328

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium nicotinate
Description: The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chromium nicotinate
Description: The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chromium nicotinate
Description: The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
Study: NCT02139592

Intervention type: DRUG
Intervention: Brentuximab vedotin (recombinant)
Description: Brentuximab vedotin (recombinant) for IV infusion
Study: NCT03205449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)
Description: The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Effectiveness Service
Description: Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. \[12\].
Study: NCT01856218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Study: NCT01460043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathy
Description: Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
Study: NCT00251043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy for depression in pregnancy
Description: IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting education program (PEP)
Description: PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
Study: NCT01121809

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Description: Changing the dose of raltegravir from 400 mg bid to 800 mg qd

Intervention type: DRUG
Group type: OTHER
Intervention: Etravirine
Description: Changing the dose of etravirine from 200 mg bid to 400 mg qd
Study: NCT03180840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegunigalsidase alfa
Description: Pegunigalsidase alfa 2 mg/kg every 4 weeks
Study: NCT02648256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polymerase Chain Reaction on Oropharyngeal rinse
Study: NCT04198051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Form、dosage and frequency： Gastric cancer was given the SOX regimen (oxaliplatin + tegafur regimen,oxaliplatin 130mg/m2 intravenous infusion, the 1st day; tegafur 80mg/ m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle) or XELOX regimen (oxaliplatin + capecitabine regimen，oxaliplatin 130mg/m2 intravenous infusion, the 1st day; capecitabine 1000mg/m2/d orally Bid, the 1st to 14th day, every 21 days is one cycle).~Colon cancer was given the XELOX regimen (the dosage、frequency and administration are the same as the gastric cancer) or FOLFOX regimen (oxaliplatin + calcium folinate + fluorouracil regimen，oxaliplatin 85mg/m2 intravenous infusion, the 1st day; calcium folinate 400 mg/m2 intravenous infusion, the 1st day; fluorouracil 400 mg/m2 intravenous infusion, the 1st day, then 1200 mg/m2/d × 2d continuous intravenous infusion，every 14 days is one cycle).~Duration：through chemotherapy completion，about six months.
Study: NCT03828071

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous hematopoietic stem cell transplantation
Description: Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was \< 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition.
Study: NCT01149148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS Somanetics Cerebral Oximeter
Description: Sequence of Interventions To Increase Cerebral Oxygen Saturation~1. Check head and cannula position~2. Increase mean arterial pressure~3. Increase pump flow~4. Increase systemic oxygenation~5. Increase PaCO2 \> 45~6. Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~7. Consider PRBC transfusion for Hct \< 21%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INVOS Somanetics Cerebral Oximeter
Description: INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
Study: NCT03855826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifekalant hydrochloride
Description: Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
Study: NCT00665457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Study: NCT03855826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
Study: NCT00665457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiomammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Study: NCT05736900

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sampling
Description: One samples of 5 mL blood is taken into a Serum tube for measurement of the RAAS-Biomarkers. After allowing to coagulate between 30 min and 60 min at room temperature, samples are centrifuged at 3000g for 10 min at room temperature.
Study: NCT04264481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Ultrasound guided perineural injection of 5cc bupivacaine, 5cc lidocaine and 10 cc Normal saline
Study: NCT00513409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 1 or 2 doses
Study: NCT04264481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Steroid and Lignocaine Injection
Description: Intra-articular injection of 40mg triamcinolone and 1-2 cc of lidocaine
Study: NCT03202602

Intervention type: OTHER
Intervention: Telemonitoring of CPAP treatment
Description: Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.

Intervention type: OTHER
Intervention: Standard care
Description: Office visits and monitoring of CPAP treatment at each visit.
Study: NCT02431962

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Low dose chest CT screening annually x 3
Study: NCT04132713

Intervention type: DRUG
Intervention: Capecitabine 150Mg Oral Tablet
Description: Advanced breast cancer patients with first-line medication
Study: NCT02431962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active smokers - Smoking cessation arm
Description: Phone based smoking cessation counseling
Study: NCT01241929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Description: video of CPR
Study: NCT02431962

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active smokers - Control arm
Description: Subjects will be provided with general information on available smoking cessation resources
Study: NCT03260751

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zingiber officinale Roscoe extract 200 mg
Description: 2 cap/day, 800 mg/cap for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks
Study: NCT01777113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aerobic training
Description: The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Strength Training
Description: Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Training
Description: Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
Study: NCT03755804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Given intravenously (IV)
Study: NCT03201107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty.
Study: NCT00883727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell
Description: IV infusion of stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Plasmalyte A
Description: IV infusion
Study: NCT03755804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given orally (PO)
Study: NCT00513409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa
Description: 1 Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix Hexa
Description: 1 Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: 1 Intramuscular injection
Study: NCT01107678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Snacks and Organized Physical Activity
Description: Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Snacks and Organized Physical Activity
Description: Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais